319 related articles for article (PubMed ID: 22232563)
1. Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α.
Han XX; Guo CM; Li Y; Hui YN
Mol Vis; 2012; 18():1-9. PubMed ID: 22232563
[TBL] [Abstract][Full Text] [Related]
2. Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy.
Chung EJ; Kang SJ; Koo JS; Choi YJ; Grossniklaus HE; Koh HJ
Yonsei Med J; 2011 Jan; 52(1):151-7. PubMed ID: 21155048
[TBL] [Abstract][Full Text] [Related]
3. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
4. Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.
Ozer F; Tokuc EO; Albayrak MGB; Akpinar G; Kasap M; Karabas VL
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1899-1906. PubMed ID: 35028761
[TBL] [Abstract][Full Text] [Related]
5. Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients.
Feng J; Li B; Wen J; Jiang Y
Ophthalmic Res; 2018; 60(4):250-257. PubMed ID: 30380554
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Ma Y; Zhang Y; Zhao T; Jiang YR
Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
[TBL] [Abstract][Full Text] [Related]
7. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
8. Short Term Effect of Pre-Operative Anti-VEGF on Angiogenic and Fibrotic Profile of Fibrovascular Membranes of Proliferative Diabetic Retinopathy.
Fadakar K; Rahmani S; Tedeschi T; Lavine JA; Fawzi AA
Invest Ophthalmol Vis Sci; 2024 Apr; 65(4):37. PubMed ID: 38652648
[TBL] [Abstract][Full Text] [Related]
9. Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression.
Zhang D; Lv FL; Wang GH
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(16):5071-5076. PubMed ID: 30178824
[TBL] [Abstract][Full Text] [Related]
10. Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab.
Zhang Y; Jiang YR; Lu Q; Yin H; Tao Y
Retina; 2013 Mar; 33(3):613-20. PubMed ID: 23296045
[TBL] [Abstract][Full Text] [Related]
11. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection.
Kohno R; Hata Y; Mochizuki Y; Arita R; Kawahara S; Kita T; Miyazaki M; Hisatomi T; Ikeda Y; Aiello LP; Ishibashi T
Am J Ophthalmol; 2010 Aug; 150(2):223-229.e1. PubMed ID: 20542485
[TBL] [Abstract][Full Text] [Related]
12. A comparison of hypoxia-inducible factor-α in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients.
Lim JI; Spee C; Hinton DR
Retina; 2010 Oct; 30(9):1472-8. PubMed ID: 20811317
[TBL] [Abstract][Full Text] [Related]
13. Altered vascular microenvironment by bevacizumab in diabetic fibrovascular membrane.
Nakao S; Ishikawa K; Yoshida S; Kohno R; Miyazaki M; Enaida H; Kono T; Ishibashi T
Retina; 2013 May; 33(5):957-63. PubMed ID: 23503340
[TBL] [Abstract][Full Text] [Related]
14. Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy.
Ushida H; Kachi S; Asami T; Ishikawa K; Kondo M; Terasaki H
Ophthalmic Res; 2013; 49(1):30-6. PubMed ID: 23038607
[TBL] [Abstract][Full Text] [Related]
15. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy.
Wang X; Wang G; Wang Y
Am J Ophthalmol; 2009 Dec; 148(6):883-9. PubMed ID: 19837381
[TBL] [Abstract][Full Text] [Related]
16. Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab.
Kubota T; Morita H; Tou N; Nitta N; Tawara A; Satoh H; Shimajiri S
Retina; 2010 Mar; 30(3):468-72. PubMed ID: 19952991
[TBL] [Abstract][Full Text] [Related]
17. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy.
Suzuki Y; Suzuki K; Yokoi Y; Miyagawa Y; Metoki T; Nakazawa M
Retina; 2014 Jan; 34(1):165-71. PubMed ID: 23851630
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy.
Li B; Li MD; Ye JJ; Chen Z; Guo ZJ; Di Y
Chin Med J (Engl); 2020 Mar; 133(6):664-669. PubMed ID: 32068603
[TBL] [Abstract][Full Text] [Related]
19. Chlorogenic acid attenuates diabetic retinopathy by reducing VEGF expression and inhibiting VEGF-mediated retinal neoangiogenesis.
Mei X; Zhou L; Zhang T; Lu B; Sheng Y; Ji L
Vascul Pharmacol; 2018 Feb; 101():29-37. PubMed ID: 29146180
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.
Forooghian F; Kertes PJ; Eng KT; Agrón E; Chew EY
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2388-92. PubMed ID: 20007836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
